PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930143
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930143
Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of prostate cancer hormone therapy Market
The global prostate cancer hormone therapy market demonstrates strong growth potential, driven by the rising prevalence of prostate cancer, increasing diagnosis rates among the aging male population, and continuous advancements in hormonal treatment strategies. As per the 2025 report year, the market was valued at USD 20.44 billion in 2025 and is projected to expand to USD 27.79 billion in 2026. Over the long-term forecast horizon, the market is expected to reach a substantial value of USD 83.1 billion by 2034, reflecting widespread adoption of androgen deprivation therapy (ADT) and next-generation hormone-based drugs.
Hormone therapy remains a cornerstone in prostate cancer treatment, particularly for advanced and metastatic disease stages. Prostate cancer growth is strongly influenced by androgens such as testosterone, and therapies that suppress or block these hormones significantly slow disease progression. Due to its clinical effectiveness, hormone therapy is commonly used as a first-line treatment in metastatic prostate cancer and increasingly in combination with other therapeutic modalities.
Market Overview and Key Insights
In 2025, North America dominated the prostate cancer hormone therapy market with a 52.30% share, accounting for a regional market value of USD 10.69 billion. This dominance is supported by strong reimbursement policies, advanced oncology infrastructure, and early adoption of innovative hormone therapies. The United States leads the region due to high research investments, robust clinical trial pipelines, and frequent regulatory approvals for novel drugs.
Europe holds the second-largest share, supported by cost-effectiveness endorsements from healthcare authorities and high disease awareness. The Asia Pacific region is projected to be the fastest-growing, driven by an expanding geriatric population, increasing prostate cancer incidence, and accelerating regulatory approvals in countries such as Japan and China.
Market Dynamics
Market Drivers
Advancements in hormonal therapies are a major driver of market growth. Traditional androgen deprivation therapy often leads to resistance over time, prompting pharmaceutical companies to develop androgen receptor inhibitors and combination therapies that improve survival outcomes. Regulatory approvals for advanced therapies continue to strengthen treatment availability across disease stages.
Market Restraints
A key restraint is the development of resistance to hormone therapy. Over prolonged treatment periods, prostate cancer cells adapt through androgen receptor mutations or alternative androgen synthesis pathways. These mechanisms reduce treatment efficacy and necessitate additional therapeutic interventions, impacting long-term treatment continuity.
Market Challenges
Hormone therapy is associated with adverse effects such as erectile dysfunction, reduced libido, and fatigue. Clinical data indicate that over 80.0% of patients undergoing ADT experience erectile dysfunction, while approximately 64.0% report loss of sexual desire. These side effects can significantly affect patient quality of life and influence therapy adherence.
Market Opportunities
Research and development of combination therapies, particularly pairing ADT with PARP inhibitors or novel targeted agents, presents strong growth opportunities. Clinical trial results demonstrating improved survival and reduced mortality risk are encouraging broader adoption of combination treatment strategies.
Market Trends
A prominent trend in the market is the increasing approval and adoption of long-acting depot formulations. These sustained-release therapies improve patient adherence by reducing dosing frequency and minimizing hormonal fluctuations, especially in elderly patients. Regulatory agencies across multiple regions are supporting such innovations to enhance patient-centric prostate cancer care.
Segmentation Analysis
By Drug Class
The Gonadotropin-Releasing Hormone (GnRH) agonists segment held the largest market share due to proven effectiveness in testosterone suppression and widespread clinical use. GnRH receptor antagonists are expected to grow rapidly owing to faster testosterone suppression and rising regulatory approvals. The androgen receptor inhibitors segment is also expanding significantly due to increasing indication approvals.
By Disease State
The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest share, driven by high disease burden and frequent regulatory approvals. The non-metastatic segment is anticipated to grow faster as companies expand drug indications to earlier disease stages.
By Route of Administration
The oral route dominates the market due to convenience, improved adherence, and increasing availability of generic drugs. Parenteral therapies hold a smaller share but continue to gain relevance through ongoing clinical trials.
By Distribution Channel
Hospital pharmacies maintain a leading share due to specialist oversight and access to advanced therapies, while online pharmacies are gaining traction with rising digital adoption.
Competitive Landscape
The prostate cancer hormone therapy market is moderately consolidated, with key players including Astellas Pharma Inc., Pfizer Inc., Bayer AG, and Johnson & Johnson Services, Inc.. These companies continue to strengthen their market positions through product launches, regulatory approvals, acquisitions, and strategic collaborations aimed at expanding global access to advanced hormone therapies.
Report Scope
The 2025 prostate cancer hormone therapy market report provides comprehensive coverage of market size and value for 2025, 2026, and 2034, along with detailed insights into market dynamics, trends, segmentation, regional performance, competitive landscape, and recent industry developments. The analysis emphasizes regulatory progress, innovation in hormone therapy, and the evolving treatment paradigm shaping long-term market expansion.
Conclusion
The prostate cancer hormone therapy market is set for sustained and robust expansion over the forecast period, supported by a strong clinical foundation and continuous therapeutic innovation. With a market value of USD 20.44 billion in 2025, projected to rise to USD 27.79 billion in 2026 and further escalate to USD 83.1 billion by 2034, the market outlook reflects the growing dependence on hormone-based treatments across multiple stages of prostate cancer. The central role of androgen deprivation therapy, combined with the rapid uptake of next-generation androgen receptor inhibitors and combination regimens, continues to redefine treatment standards.
North America's leadership, holding 52.30% market share in 2025, underscores the importance of advanced healthcare infrastructure, favorable reimbursement policies, and strong research ecosystems, while Europe and Asia Pacific contribute significantly through cost-effective treatment access and expanding patient populations. Despite challenges such as therapy resistance and treatment-related adverse effects, ongoing research, regulatory approvals, and the shift toward long-acting formulations and combination therapies are mitigating these limitations. Overall, the market is well-positioned for long-term growth through 2034, driven by innovation, expanding indications, and the increasing global burden of prostate cancer.
Segmentation By Drug Class
- Androgen Receptor Inhibitors
- Gonadotropin Releasing Hormone (GnRH) Agonist
- Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- Others
By Route of Administration
- Oral
- Parenteral
By Disease State
- Metastatic Castration-Resistant Prostate Cancer
- Non-Metastatic Castration-Resistant Prostate Cancer
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
- 4.2. Pipeline Analysis, by Key Players
- 4.3. Overview of Alternative Therapies
- 4.4. Key Start-ups in the Market
- 4.5. New Product Launches, by Key Players
- 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.7. Impact of COVID-19 on the Market
5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Androgen Receptor Inhibitors
- 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Disease State
- 5.3.1. Metastatic Castration-Resistant Prostate Cancer
- 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Androgen Receptor Inhibitors
- 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Disease State
- 6.3.1. Metastatic Castration-Resistant Prostate Cancer
- 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Androgen Receptor Inhibitors
- 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Disease State
- 7.3.1. Metastatic Castration-Resistant Prostate Cancer
- 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Androgen Receptor Inhibitors
- 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Disease State
- 8.3.1. Metastatic Castration-Resistant Prostate Cancer
- 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Androgen Receptor Inhibitors
- 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Disease State
- 9.3.1. Metastatic Castration-Resistant Prostate Cancer
- 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Androgen Receptor Inhibitors
- 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Disease State
- 10.3.1. Metastatic Castration-Resistant Prostate Cancer
- 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Astellas Pharma Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Pfizer Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Ferring Pharmaceuticals Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. AbbVie Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. AstraZeneca
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Accord BioPharma, Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bayer AG
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Astellas Pharma Inc.
List of Tables
- Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
- Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025 & 2034
- Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2025 & 2034
- Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
- Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
- Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
- Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2025
- Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
- Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
- Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
- Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
- Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
- Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
- Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
- Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
- Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
- Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
- Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
- Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
- Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2025
